4119 Stock Overview
Together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
SCI Pharmtech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$85.70 |
| 52 Week High | NT$98.80 |
| 52 Week Low | NT$82.50 |
| Beta | -0.24 |
| 1 Month Change | -5.41% |
| 3 Month Change | -4.78% |
| 1 Year Change | -7.15% |
| 3 Year Change | 17.15% |
| 5 Year Change | 14.55% |
| Change since IPO | 332.10% |
Recent News & Updates
Recent updates
Shareholders Shouldn’t Be Too Comfortable With SCI Pharmtech's (TWSE:4119) Strong Earnings
Nov 17
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings
Mar 27Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates
Apr 07There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings
Mar 30SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?
Mar 08SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years
Jan 25
Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates
Dec 30Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?
Dec 29Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?
Dec 08A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)
Nov 17Shareholder Returns
| 4119 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -7.2% | -0.2% | 28.0% |
Return vs Industry: 4119 underperformed the TW Pharmaceuticals industry which returned 0.4% over the past year.
Return vs Market: 4119 underperformed the TW Market which returned 28.6% over the past year.
Price Volatility
| 4119 volatility | |
|---|---|
| 4119 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4119 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4119's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Wen-Chih Chou | www.sci-pharmtech.com.tw |
SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBD. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz.
SCI Pharmtech, Inc. Fundamentals Summary
| 4119 fundamental statistics | |
|---|---|
| Market cap | NT$10.24b |
| Earnings (TTM) | NT$484.24m |
| Revenue (TTM) | NT$1.41b |
21.2x
P/E Ratio7.2x
P/S RatioIs 4119 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4119 income statement (TTM) | |
|---|---|
| Revenue | NT$1.41b |
| Cost of Revenue | NT$1.03b |
| Gross Profit | NT$383.22m |
| Other Expenses | -NT$101.02m |
| Earnings | NT$484.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.05 |
| Gross Margin | 27.11% |
| Net Profit Margin | 34.26% |
| Debt/Equity Ratio | 20.3% |
How did 4119 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 04:10 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SCI Pharmtech, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Regina Lee | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |